复宏汉霖(02696)今日盘中出现大涨行情,截至下午2点35分,该股股价上涨5.22%,报16.94港元。从消息面来看,该公司旗下创新药研究取得了进展,成为推动股价上涨的主因。
1月26日,复宏汉霖宣布其自主研发的重组人源化抗PD-1单抗注射液H药汉斯状和抗HER2单克隆抗体HLX22的最新研究结果在2025年美国临床肿瘤学会胃肠道肿瘤研讨会(ASCOGI)上发布。其中,H药汉斯状是全球首个获批一线治疗小细胞肺癌的抗PD-1单抗,已在中国和多个东南亚国家获批上市。HLX22的国际多中心III期临床试验相继获中国、美国、日本、澳大利亚临床试验许可。
这些临床研究进展表明,复宏汉霖在生物技术创新药领域的持续创新能力获得市场认可。随着创新药产品线拓展,公司在未来的持续收入增长方面具有较强的预期,从而推动股价上扬。对于该公司未来发展前景,投资者给予了较高的评价和期望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.